S&P 500   0.72 (+6.87%)
DOW   0.72 (+6.87%)
QQQ   271.86 (+2.52%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.72 (+6.87%)
DOW   0.72 (+6.87%)
QQQ   271.86 (+2.52%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.72 (+6.87%)
DOW   0.72 (+6.87%)
QQQ   271.86 (+2.52%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.72 (+6.87%)
DOW   0.72 (+6.87%)
QQQ   271.86 (+2.52%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
Log in

NASDAQ:NVCRNovocure Stock Price, Forecast & News

$75.00
+0.46 (+0.62 %)
(As of 08/13/2020 04:00 PM ET)
Add
Compare
Today's Range
$74.21
Now: $75.00
$75.32
50-Day Range
$57.20
MA: $66.32
$79.04
52-Week Range
$53.40
Now: $75.00
$98.84
Volume341,100 shs
Average Volume983,782 shs
Market Capitalization$7.58 billion
P/E Ratio625.05
Dividend YieldN/A
Beta1.62
Novocure Ltd. is global oncology company, which engages in the development and commercialization of its innovative therapy. It focuses on the commercial adoption of Optune, and its Tumor Treating Fields delivery system, for the treatment of glioblastoma (GBM), and to advance programs testing the efficacy and safety of Optune in multiple solid tumor indications through clinical pipeline. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.
Read More
Novocure logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.2Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.33 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NVCR
CUSIPN/A
Phone44-0-15-3475-6700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$351.32 million
Book Value$2.20 per share

Profitability

Net Income$-7,230,000.00

Miscellaneous

EmployeesN/A
Market Cap$7.58 billion
Next Earnings Date10/29/2020 (Estimated)
OptionableOptionable
$75.00
+0.46 (+0.62 %)
(As of 08/13/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NVCR News and Ratings via Email

Sign-up to receive the latest news and ratings for NVCR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Novocure (NASDAQ:NVCR) Frequently Asked Questions

How has Novocure's stock price been impacted by Coronavirus?

Novocure's stock was trading at $67.38 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, NVCR shares have increased by 11.3% and is now trading at $75.00.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Novocure?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novocure in the last year. There are currently 1 sell rating, 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Novocure
.

When is Novocure's next earnings date?

Novocure is scheduled to release its next quarterly earnings announcement on Thursday, October 29th 2020.
View our earnings forecast for Novocure
.

How were Novocure's earnings last quarter?

Novocure Ltd (NASDAQ:NVCR) posted its quarterly earnings data on Thursday, July, 30th. The medical equipment provider reported $0.02 earnings per share for the quarter, beating analysts' consensus estimates of $0.01 by $0.01. The medical equipment provider earned $115.90 million during the quarter, compared to analyst estimates of $105.96 million. Novocure had a net margin of 2.88% and a return on equity of 5.14%. The firm's revenue for the quarter was up 33.7% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.01) earnings per share.
View Novocure's earnings history
.

What price target have analysts set for NVCR?

8 analysts have issued 12-month target prices for Novocure's stock. Their forecasts range from $58.00 to $90.00. On average, they expect Novocure's share price to reach $79.75 in the next twelve months. This suggests a possible upside of 6.3% from the stock's current price.
View analysts' price targets for Novocure
.

Has Novocure been receiving favorable news coverage?

Media headlines about NVCR stock have trended negative this week, according to InfoTrie Sentiment. The research firm scores the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Novocure earned a news impact score of -2.4 on InfoTrie's scale. They also assigned media stories about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term.
View the latest news about Novocure
.

Are investors shorting Novocure?

Novocure saw a decline in short interest during the month of June. As of June 30th, there was short interest totaling 3,380,000 shares, a decline of 17.0% from the June 15th total of 4,070,000 shares. Based on an average daily volume of 987,800 shares, the short-interest ratio is presently 3.4 days. Approximately 4.1% of the shares of the stock are short sold.
View Novocure's Short Interest
.

Who are some of Novocure's key competitors?

What other stocks do shareholders of Novocure own?

Who are Novocure's key executives?

Novocure's management team includes the following people:
  • Asaf Danziger, Chief Executive Officer & Director
  • Mike Ambrogi, Chief Operating Officer
  • Wilco Groenhuysen, CFO & Chief Accounting Officer
  • Eilon D. Kirson, Chief Science Officer, Head-Research & Development
  • Uri Weinberg, Vice President-Clinical Development

What is Novocure's stock symbol?

Novocure trades on the NASDAQ under the ticker symbol "NVCR."

Who are Novocure's major shareholders?

Novocure's stock is owned by a number of retail and institutional investors. Top institutional shareholders include FMR LLC (10.33%), Macquarie Group Ltd. (0.93%), Rhenman & Partners Asset Management AB (0.37%), Goldman Sachs Group Inc. (0.37%), C WorldWide Group Holding A S (0.34%) and Hartline Investment Corp (0.33%). Company insiders that own Novocure stock include Asaf Danziger, Charles G Phillips III, Ely Benaim, Gabriel Leung, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Wilhelmus Cm Groenhuysen, William F Doyle and Yoram Palti.
View institutional ownership trends for Novocure
.

Which major investors are selling Novocure stock?

NVCR stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Macquarie Group Ltd., Frontier Capital Management Co. LLC, Healthcare of Ontario Pension Plan Trust Fund, Nicholas Investment Partners LP, American International Group Inc., Bank of New York Mellon Corp, and Goldman Sachs Group Inc.. Company insiders that have sold Novocure company stock in the last year include Asaf Danziger, Charles G Phillips III, Ely Benaim, Gabriel Leung, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Wilhelmus Cm Groenhuysen, and William F Doyle.
View insider buying and selling activity for Novocure
.

Which major investors are buying Novocure stock?

NVCR stock was acquired by a variety of institutional investors in the last quarter, including C WorldWide Group Holding A S, Kornitzer Capital Management Inc. KS, New York State Common Retirement Fund, State Board of Administration of Florida Retirement System, Bullseye Asset Management LLC, Peregrine Capital Management LLC, Swiss National Bank, and Phoenix Holdings Ltd..
View insider buying and selling activity for Novocure
.

How do I buy shares of Novocure?

Shares of NVCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Novocure's stock price today?

One share of NVCR stock can currently be purchased for approximately $75.00.

How big of a company is Novocure?

Novocure has a market capitalization of $7.58 billion and generates $351.32 million in revenue each year. The medical equipment provider earns $-7,230,000.00 in net income (profit) each year or ($0.07) on an earnings per share basis.

What is Novocure's official website?

The official website for Novocure is www.novocure.com.

How can I contact Novocure?

Novocure's mailing address is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. The medical equipment provider can be reached via phone at 44-0-15-3475-6700 or via email at [email protected]

This page was last updated on 8/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.